| Inventor(s): | Feng; Jun (Carlsbad, CA), Gwaltney; Stephen L. (San Diego, CA), Stafford; Jeffrey A. (San Diego, CA), Zhang; Zhiyuan (San Diego, CA), Elder; Bruce J. (Wynantskill, NY), Isbester; Paul K. (Castleton, NY), Palmer; Grant J. (Clifton Park, NY), Salsbury; Jonathon S. (Albany, NY), Ulysse; Luckner G. (Albany, NY) |
|
Patent landscape, scope, and claims: |
United States Patent 8,288,539: A Detailed Analysis of Scope, Claims, and Patent Landscape
Introduction
United States Patent 8,288,539, titled "Dipeptidyl Peptidase Inhibitors," is a significant patent held by Takeda Pharmaceutical Company Limited. This patent is crucial in the pharmaceutical industry, particularly in the development and marketing of drugs related to dipeptidyl peptidase-4 (DPP-4) inhibitors. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.
Background and Inventors
The patent was granted on October 16, 2012, to inventors Jun Feng, Stephen L. Gwaltney, Jeffrey A. Stafford, Zhiyuan Zhang, Bruce J. Elder, Paul K. Isbester, Grant J. Palmer, and Luckner G. Ulysse, all associated with Takeda Pharmaceutical Company Limited[4][5].
Scope of the Patent
The patent covers dipeptidyl peptidase inhibitors, which are a class of drugs used to treat type 2 diabetes. These inhibitors work by blocking the enzyme DPP-4, thereby increasing the levels of incretin hormones, which in turn stimulate the release of insulin and decrease the release of glucagon. The scope of the patent includes various compounds and their methods of preparation, as well as their use in treating diabetes and other related conditions[1][5].
Claims of the Patent
The patent includes multiple claims that define the scope of the invention. These claims are divided into several categories:
- Compound Claims: These claims specify the chemical structures of the dipeptidyl peptidase inhibitors.
- Method of Preparation Claims: These claims describe the processes for synthesizing the inhibitors.
- Use Claims: These claims outline the therapeutic uses of the inhibitors, particularly in treating type 2 diabetes.
- Pharmaceutical Composition Claims: These claims cover the formulations and combinations of the inhibitors with other drugs, such as metformin[1][4].
Patent Landscape and Related Patents
The patent landscape surrounding US 8,288,539 is complex and involves several related patents. Here are a few key points:
- Related Patents: Takeda holds several other patents related to dipeptidyl peptidase inhibitors, including US 7,807,689, US 8,173,663, and US 8,900,638. These patents collectively protect various aspects of the drug, including different compounds, formulations, and methods of use[4].
- Kazano: The drug product Kazano, which combines alogliptin benzoate (a DPP-4 inhibitor) and metformin hydrochloride, is protected under these patents. Takeda has asserted these patents in litigation against generic manufacturers seeking to market similar products[4].
Regulatory and Litigation Context
The patent has been involved in several regulatory and litigation activities:
- Patent Term Restoration: The patent term for US 8,288,539 was extended due to regulatory delays, a common practice to ensure that the effective patent life is not significantly reduced by the time spent in regulatory review[2].
- Litigation: Takeda has engaged in patent infringement litigation against companies like Indoco Remedies, which sought to market generic versions of Kazano. These lawsuits highlight the importance of these patents in protecting Takeda's intellectual property and market share[4].
Impact on the Pharmaceutical Industry
The patent and its related claims have significant implications for the pharmaceutical industry:
- Innovation and Investment: The robust patent protection provided by US 8,288,539 and related patents is crucial for innovators to recoup their investment in research and development. The pharmaceutical industry invests billions of dollars in bringing new drugs to market, and strong patent protection is essential for this investment to be viable[3].
- Generic Competition: The patent claims and their enforcement play a critical role in delaying the entry of generic competitors. This allows the original innovator to maintain market exclusivity and recoup their investment before generic versions can enter the market[4].
Challenges in Patent Claims and Genus Claims
The pharmaceutical and biotechnology industries face unique challenges in drafting and enforcing patent claims, particularly genus claims:
- Genus Claims: These claims cover a broad class of compounds rather than specific embodiments. However, recent jurisprudence has made it challenging to obtain and maintain genus claims due to stringent requirements for written description and enablement under 35 U.S.C. § 112(a)[3].
- Enablement and Written Description: The Federal Circuit's rigid position on these requirements has made it difficult for innovators to claim the full scope of their inventions without violating these rules. This has led to a situation where innovators are caught between claiming too broadly and risking invalidation or claiming too narrowly and allowing competitors to design around the claims[3].
Market and Economic Impact
The market for therapeutic drugs, including DPP-4 inhibitors, is substantial and growing:
- Market Size: The market for therapeutic antibodies and biologics, which includes drugs like those protected by US 8,288,539, is projected to reach $300 billion by 2025. Strong patent protection is essential for companies to capture a significant share of this market[3].
- Competitive Landscape: The enforcement of patents like US 8,288,539 helps maintain a competitive landscape where innovators can protect their inventions and maintain market exclusivity, which is crucial for their business strategies[4].
Key Takeaways
- Scope and Claims: US 8,288,539 covers dipeptidyl peptidase inhibitors, including their chemical structures, methods of preparation, and therapeutic uses.
- Related Patents: The patent is part of a broader portfolio protecting Takeda's drug product Kazano.
- Regulatory and Litigation Context: The patent has been extended due to regulatory delays and has been involved in litigation to protect against generic competition.
- Industry Impact: Strong patent protection is crucial for innovation and investment in the pharmaceutical industry.
- Challenges in Patent Claims: Recent jurisprudence has made it challenging to obtain and maintain genus claims, affecting the scope of patent protection.
FAQs
What is the main subject of United States Patent 8,288,539?
The main subject of US 8,288,539 is dipeptidyl peptidase inhibitors, specifically their use in treating type 2 diabetes.
Who are the inventors and assignees of the patent?
The inventors include Jun Feng, Stephen L. Gwaltney, Jeffrey A. Stafford, Zhiyuan Zhang, Bruce J. Elder, Paul K. Isbester, Grant J. Palmer, and Luckner G. Ulysse. The assignee is Takeda Pharmaceutical Company Limited.
What is the significance of Kazano in relation to this patent?
Kazano is a drug product that combines alogliptin benzoate (a DPP-4 inhibitor) and metformin hydrochloride, protected under this and related patents.
How has recent jurisprudence affected genus claims in pharmaceutical patents?
Recent jurisprudence has made it challenging to obtain and maintain genus claims due to stringent requirements for written description and enablement under 35 U.S.C. § 112(a), affecting the scope of patent protection in the pharmaceutical industry.
What is the projected market size for therapeutic antibodies and biologics by 2025?
The market for therapeutic antibodies and biologics is projected to reach $300 billion by 2025.
Cited Sources
- United States Patent and Trademark Office, "Dipeptidyl Peptidase Inhibitors," US Patent 8,288,539 B2, October 16, 2012.
- Federal Register, "Determination of Regulatory Review Period for Purposes of Patent Extension—Kazano," May 4, 2015.
- DigitalCommons@NYLS, "Eviscerating Patent Scope," accessed December 19, 2024.
- PharmaCompass, "Takeda Pharmaceutical Co Ltd v Indoco Remedies Ltd," accessed December 19, 2024.
- Unified Patents Portal, "US-20110212982-A1," accessed December 19, 2024.
More… ↓
⤷ Subscribe
|
